KR20130086141A - Ｃｏｐｄ 악화를 치료하기 위한 조성물 및 방법 - Google Patents

Ｃｏｐｄ 악화를 치료하기 위한 조성물 및 방법 Download PDF

Info

Publication number
KR20130086141A
KR20130086141A KR1020127030148A KR20127030148A KR20130086141A KR 20130086141 A KR20130086141 A KR 20130086141A KR 1020127030148 A KR1020127030148 A KR 1020127030148A KR 20127030148 A KR20127030148 A KR 20127030148A KR 20130086141 A KR20130086141 A KR 20130086141A
Authority
KR
South Korea
Prior art keywords
antibody
copd
patient
exacerbation
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020127030148A
Other languages
English (en)
Korean (ko)
Inventor
도나 핀치
앤서니 코일
마틴 스탬플리
Original Assignee
메디뮨 리미티드
맥마스터 유니버시티
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 메디뮨 리미티드, 맥마스터 유니버시티 filed Critical 메디뮨 리미티드
Publication of KR20130086141A publication Critical patent/KR20130086141A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2006—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020127030148A 2010-04-16 2011-04-18 Ｃｏｐｄ 악화를 치료하기 위한 조성물 및 방법 Withdrawn KR20130086141A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US32524110P 2010-04-16 2010-04-16
US61/325,241 2010-04-16
US41610210P 2010-11-22 2010-11-22
US61/416,102 2010-11-22
PCT/US2011/032910 WO2011130745A1 (en) 2010-04-16 2011-04-18 Compositions and methods for treating copd exacerbation

Publications (1)

Publication Number Publication Date
KR20130086141A true KR20130086141A (ko) 2013-07-31

Family

ID=44799068

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020127030148A Withdrawn KR20130086141A (ko) 2010-04-16 2011-04-18 Ｃｏｐｄ 악화를 치료하기 위한 조성물 및 방법

Country Status (11)

Country Link
US (1) US20130149312A1 (https=)
EP (1) EP2558112A4 (https=)
JP (1) JP2013525310A (https=)
KR (1) KR20130086141A (https=)
CN (1) CN102985100A (https=)
AU (1) AU2011239402A1 (https=)
BR (1) BR112012026545A2 (https=)
CA (1) CA2796083A1 (https=)
MX (1) MX2012012063A (https=)
RU (1) RU2012148721A (https=)
WO (1) WO2011130745A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020231221A1 (ko) * 2019-05-16 2020-11-19 포항공과대학교 산학협력단 G-CSF 및 IL-1β를 이용한 호중구성 폐 염증질환의 진단, 예방 또는 치료용 조성물

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104740615A (zh) * 2013-12-31 2015-07-01 上海索菲里奥生物医药科技发展有限公司 IL-1β在制备用于治疗由金黄色葡萄球菌易感所引起的炎症的药物中的用途
JPWO2015182121A1 (ja) * 2014-05-29 2017-04-27 国立研究開発法人医薬基盤・健康・栄養研究所 アレルギー誘発性物質の検査、アレルギーの診断および治療
WO2016168696A1 (en) * 2015-04-15 2016-10-20 Ohio State Innovation Foundation Methods to improve induction of iga antibodies by vaccines
EP3303444A1 (en) 2015-06-05 2018-04-11 The University of Rochester Shape-memory polymers and methods of making and use thereof
US20220409627A1 (en) * 2019-12-02 2022-12-29 Altavant Sciences Gmbh Treatment of lower airways disorders
WO2026003765A1 (en) * 2024-06-25 2026-01-02 Kiniksa Pharmaceuticals, Gmbh Formulations of anti-interleukin 1 receptor 1 antibodies

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010053764A1 (en) * 2000-05-12 2001-12-20 Sims John E. Interleukin-1 inhibitors in the treatment of diseases
CA2824167C (en) * 2002-09-06 2018-09-25 Amgen Inc. Therapeutic human anti-il-1r1 monoclonal antibody
CA2588892A1 (en) * 2004-12-02 2006-06-08 Dormantis Limited Anti-il-1r1 single domain antibodies and therapeutic uses
PE20061324A1 (es) * 2005-04-29 2007-01-15 Centocor Inc Anticuerpos anti-il-6, composiciones, metodos y usos
CA2632866A1 (en) * 2005-12-01 2007-06-07 Domantis Limited Noncompetitive domain antibody formats that bind interleukin 1 receptor type 1
US8298533B2 (en) * 2008-11-07 2012-10-30 Medimmune Limited Antibodies to IL-1R1

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020231221A1 (ko) * 2019-05-16 2020-11-19 포항공과대학교 산학협력단 G-CSF 및 IL-1β를 이용한 호중구성 폐 염증질환의 진단, 예방 또는 치료용 조성물
KR20200132316A (ko) * 2019-05-16 2020-11-25 포항공과대학교 산학협력단 G-CSF 및 IL-1β를 이용한 호중구성 폐 염증질환의 진단, 예방 또는 치료용 조성물

Also Published As

Publication number Publication date
MX2012012063A (es) 2013-03-21
WO2011130745A1 (en) 2011-10-20
EP2558112A1 (en) 2013-02-20
CA2796083A1 (en) 2011-10-20
EP2558112A4 (en) 2014-06-18
US20130149312A1 (en) 2013-06-13
JP2013525310A (ja) 2013-06-20
CN102985100A (zh) 2013-03-20
AU2011239402A1 (en) 2012-10-25
RU2012148721A (ru) 2014-05-27
BR112012026545A2 (pt) 2019-09-24

Similar Documents

Publication Publication Date Title
US20240199751A1 (en) Methods for treating or preventing asthma by administering an il-4r antagonist
AU2018253118B2 (en) Treatment of asthma with anti-TSLP antibody
JP6820743B2 (ja) 炎症性疾患におけるｉｌ−１８結合タンパク質（ｉｌ−１８ｂｐ）
EP3613432A1 (en) Methods for treating nasal polyposis by administering an il-4r antagonist
KR20130086141A (ko) Ｃｏｐｄ 악화를 치료하기 위한 조성물 및 방법
JP2017535547A (ja) Ｉｌ−４ｒアンタゴニストの投与により鼻ポリープを伴う慢性副鼻腔炎を処置する方法
KR20220133234A (ko) 항-tslp 항체를 이용한 염증성 또는 폐쇄성 기도 질환의 치료 방법
KR20240049348A (ko) 항-인터루킨-33 항체를 사용한 만성 폐쇄성 폐질환의 치료
JP7216157B2 (ja) Ｉｌ－４ｒアンタゴニストを投与することにより喘息を処置又は予防するための方法
CN101022828A (zh) B因子、补体旁路的抑制及与此相关的方法
WO2025221995A1 (en) Treatment of eosinophilic esophagitis with anti-tslp antibody
HK40076109B (en) Methods for treating or preventing asthma by administering an il-4r antagonist
WO2025120567A1 (en) Method of treatment of asthma
HK40076109A (en) Methods for treating or preventing asthma by administering an il-4r antagonist
HK40006965A (en) Methods for treating or preventing asthma by administering an il-4r antagonist
WO2013032943A1 (en) Methods and compositions for the treatment of respiratory conditions via nkg2d inhibition
BR122019023269B1 (pt) composição farmacêutica compreendendo um anticorpo que se liga especificamente ao receptor da interleucina-4 (il-4r) para uso no tratamento de asma moderada a grave ou grave em um indivíduo
NZ727717B2 (en) Methods for treating or preventing asthma by administering an il-4r antagonist

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20121116

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid